Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

Employees

816

Sector

Pharmaceuticals

Calendar

Mar. 01 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-12-15	146.24 $	-1.30%	364,590
25-12-12	148.17 $	-0.39%	554,080
25-12-11	148.75 $	-0.34%	276,799
25-12-10	149.26 $	+2.78%	406,310
25-12-09	145.22 $	-1.59%	440,003

Delayed Quote Nasdaq, December 15, 2025 at 04:00 pm EST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

146.24USD

Average target price

179.74USD

Spread / Average Target

+22.91%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-15 pm EST			5-day change	1st Jan Change
146.24 ^USD	-1.30%		-0.89%	+72.84%

Dec. 12	Axsome Confident On Regulatory, Commercial Outlook for Alzheimer's Agitation Drug Candidate, RBC Says	MT
Dec. 04	Axsome Therapeutics, Inc. Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-03-2025 04:00 PM

Capitalization	7.37B 6.27B 5.87B 5.51B 10.15B 669B 11.09B 68.39B 26.43B 315B 27.66B 27.08B 1,145B	P/E ratio 2025 *	-38.6x	P/E ratio 2026 *	289x
Enterprise value	7.28B 6.19B 5.79B 5.44B 10.02B 660B 10.95B 67.51B 26.09B 311B 27.31B 26.73B 1,130B	EV / Sales 2025 *	11.6x	EV / Sales 2026 *	7.33x
Free-Float	81.71%	Yield 2025 *	-	Yield 2026 *	-

Dec. 12	Axsome Confident On Regulatory, Commercial Outlook for Alzheimer's Agitation Drug Candidate, RBC Says	MT
Dec. 04	Axsome Therapeutics, Inc. Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-03-2025 04:00 PM
Nov. 11	Axsome Therapeutics, Inc. completed the acquisition of Baergic Bio, Inc. from Avenue Therapeutics, Inc..	CI
Nov. 06	Axsome Therapeutics Acquires Subtype Selective Gaba-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy from AstraZeneca AB	CI
Nov. 06	Axsome Therapeutics acquires AZD7325, a selective GABA-A modulator for treatment of epilepsy	RE
Nov. 06	Mizuho Lifts Price Target on Axsome Therapeutics to $202 From $200, Keeps Outperform Rating	MT
Nov. 06	Axsome Therapeutics Insider Sold Shares Worth $21,815,669, According to a Recent SEC Filing	MT
Nov. 05	Axsome Therapeutics, Inc. entered into stock purchase agreement to acquire Baergic Bio, Inc. from Avenue Therapeutics, Inc. for $83.3 million.	CI
Nov. 04	B. Riley Adjusts Axsome Therapeutics Price Target to $184 From $179, Maintains Buy Rating	MT
Nov. 04	RBC Raises Price Target on Axsome Therapeutics to $198 From $189, Keeps Outperform Rating	MT
Nov. 03	Axsome Therapeutics, Inc., Q3 2025 Earnings Call, Nov 03, 2025
Nov. 03	Axsome Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 03	Axsome Therapeutics Q3 Net Loss Narrows, Revenue Rises	MT

Dec. 12	Axsome Confident On Regulatory, Commercial Outlook for Alzheimer's Agitation Drug Candidate, RBC Says	MT
Nov. 06	Mizuho Lifts Price Target on Axsome Therapeutics to $202 From $200, Keeps Outperform Rating	MT
Nov. 04	B. Riley Adjusts Axsome Therapeutics Price Target to $184 From $179, Maintains Buy Rating	MT
Nov. 04	RBC Raises Price Target on Axsome Therapeutics to $198 From $189, Keeps Outperform Rating	MT
Oct. 01	B. Riley Initiates Axsome Therapeutics at Buy With $179 Price Target	MT

Axsome Therapeutics, Inc. Stock

Equities

AXSM

US05464T1043

Pharmaceuticals

Valuation: Axsome Therapeutics, Inc.

Chart: Axsome Therapeutics, Inc.

Latest news: Axsome Therapeutics, Inc.

Last Transcript: Axsome Therapeutics, Inc.

Analysts' recommendations: Axsome Therapeutics, Inc.

Press Releases: Axsome Therapeutics, Inc.

News in other languages: Axsome Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Axsome Therapeutics, Inc.

ETFs: Axsome Therapeutics, Inc.

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Nov. 20	Axsome Therapeutics to Participate in Upcoming Investor Conferences	GL
Nov. 06	Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics	AQ
Nov. 06	Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy	GL
Nov. 06	Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy	AQ
Nov. 03	Axsome Therapeutics : Third Quarter 2025 Corporate Presentation	PU

21-06-07	Biogen : s'envole après le feu vert de la FDA à son traitement contre la maladie d'Alzheimer
19-12-16	Dow Jones Industrial Average : Les valeurs à suivre à Wall Street
19-12-16	USA-Les valeurs à suivre à Wall Street (actualisé)

1 day	-1.30%
1 week	-0.89%
Current month	-3.47%
1 month	+4.69%
3 months	+25.23%
6 months	+40.48%
Current year	+72.84%

1 week	144.13	150
1 month	138.9	152.94
Current year	79.19	152.94
1 year	75.56	152.94
3 years	53.71	152.94
5 years	19.38	152.94
10 years	1.94	152.94

Manager	Title	Age	Since
Herriott Tabuteau CEO	Chief Executive Officer	56	2012-01-11
Nick Pizzie DFI	Director of Finance/CFO	50	2018-05-15
Mark Jacobson COO	Chief Operating Officer	41	2014-03-31

Director	Title	Age	Since
Herriott Tabuteau CHM	Chairman	56	2012-01-11
Roger Jeffs BRD	Director/Board Member	63	2014-11-30
Mark Coleman BRD	Director/Board Member	57	2014-11-30

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
AXSOME THERAPEUTICS, INC.	-1.30%	-0.89%	+62.31%	+88.79%	7.37B
REGENERON PHARMACEUTICALS, INC.	+1.53%	+7.02%	+2.92%	+2.92%	77.22B
CSL LIMITED	-1.20%	-2.57%	-36.00%	-39.27%	57.5B
SAMSUNG BIOLOGICS CO.,LTD.	+4.73%	+77.20%	+77.20%	+77.20%	55.88B
UCB	+1.19%	-4.07%	+31.80%	+223.24%	53.2B
BIOGEN INC.	+0.94%	-2.60%	+17.14%	-38.00%	25.78B
INNOVENT BIOLOGICS, INC.	-2.69%	-5.81%	+119.31%	+146.13%	18B
INCYTE CORPORATION	+3.39%	+2.01%	+43.89%	+19.96%	19.37B
ALTEOGEN INC.	+0.69%	-4.80%	+37.54%	+1,019.38%	15.88B
BRIDGEBIO PHARMA, INC.	-0.85%	+0.36%	+171.04%	+736.25%	14.36B
Average	+0.63%	-0.39%	+52.72%	+223.66%	34.46B
Weighted average by Cap.	+1.18%	+0.95%	+32.25%	+126.58%

	2025 *	2026 *
Net sales	630M 536M 501M 471M 868M 57.16B 948M 5.85B 2.26B 26.9B 2.36B 2.31B 97.84B	979M 832M 779M 731M 1.35B 88.79B 1.47B 9.08B 3.51B 41.79B 3.67B 3.6B 152B
Net income	-188M -160M -150M -141M -259M -17.06B -283M -1.74B -674M -8.03B -706M -691M -29.2B	22.58M 19.2M 17.97M 16.87M 31.09M 2.05B 33.97M 209M 80.96M 964M 84.73M 82.94M 3.51B
Net Debt	-94.35M -80.23M -75.08M -70.51M -130M -8.56B -142M -875M -338M -4.03B -354M -347M -14.65B	-199M -169M -159M -149M -274M -18.07B -300M -1.85B -714M -8.51B -748M -732M -30.94B